TLX Panoramica delle azioni Telix Pharmaceuticals Limited, una società biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di radiofarmaci terapeutici e diagnostici per il cancro e le malattie rare in Australia, Belgio, Giappone, Svizzera e Stati Uniti. Maggiori dettagli
Premi Analisi del rischio Vedi tutti gli assegni di rischio Catturate i vostri pensieri, i link e la narrativa aziendale
Telix Pharmaceuticals Limited Concorrenti Storia dei prezzi e prestazioni
Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Telix Pharmaceuticals Prezzi storici delle azioni Prezzo attuale dell'azione AU$24.61 Massimo di 52 settimane AU$25.80 Minimo di 52 settimane AU$9.13 Beta 2.41 Variazione di 1 mese -0.53% Variazione a 3 mesi 20.70% Variazione di 1 anno 144.15% Variazione a 3 anni 199.39% Variazione a 5 anni 1,438.13% Variazione dall'IPO 3,096.10%
Notizie e aggiornamenti recenti
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy Vedi altri aggiornamenti
Telix Pharmaceuticals Limited Completes the Installation of Two New Cyclotron at Telix Manufacturing Solutions in Brussels South, Belgium Dec 19
Telix Pharmaceuticals Limited and Grand Pharmaceutical Group Limited Announces First Patient Dosed in Phase III ZIRCON-CP Trial of TLX250-CDx for Kidney Cancer Imaging in Chinese Patients Nov 28
Telix Pharmaceuticals Limited Announces FDA Accepts New Drug Application and Grants Priority Review for TLX101-CDx Brain Cancer Imaging Agent Oct 24 Telix Pharmaceuticals Limited Announces Retirement of Andreas Kluge from the Board of Directors
Australian TGA Approves Additional Indication for Telix's Illuccix® to Include Patient Selection for PSMA-Targeted Therapy Oct 08 Health Canada Approves Label Expansion for Telix Pharmaceuticals Limited's Illuccix to Include Patient Selection for PSMA-Targeted Therapy
Telix Pharmaceuticals Initiates Phase II Trial for Tlx250-Cdx in Recurrent Clear Cell Renal Cell Carcinoma Oct 03
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire RLS (USA) Inc. from Rls Group Ltd for $250 million. Sep 23
Consensus EPS estimates fall by 23% Aug 29
Telix Submits NDA for TLX101-Cdx (Pixclara®) Brain Cancer Imaging Agent Aug 28
Second quarter 2024 earnings: EPS misses analyst expectations Aug 23
Telix Pharmaceuticals Limited Announces Expanded Access Program Opens in the U.S. for Tlx101-Cdx, Telix’s Investigational Glioma (Brain Cancer) Imaging Agent Jul 30
Price target increased by 12% to AU$24.04 Jul 24
Price target increased by 10% to AU$20.87 Jul 19 Telix Pharmaceuticals Limited Updates Earnings Guidance for the Fiscal Year 2024
Price target increased by 14% to AU$21.49 Jul 12
Consensus EPS estimates increase by 10% Jul 12
Price target increased by 11% to AU$18.89 Jun 18 Telix Pharmaceuticals Limited has withdrawn its Follow-on Equity Offering in the amount of $201.79 million. Jun 15
First quarter 2024 earnings released: EPS: AU$0.056 (vs AU$0.027 loss in 1Q 2023) Jun 06
Telix Pharmaceuticals Limited Submits NDA for New Prostate Cancer Imaging Agent May 28
Consensus EPS estimates increase by 10% May 22
Telix Pharmaceuticals Limited has filed an IPO in the amount of $100 million. May 18
Consensus EPS estimates increase by 30% Apr 18 Telix Pharmaceuticals Limited Reaffirms Revenue Guidance for the Year 2024
Now 20% overvalued after recent price rise Apr 12 Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of ARTMS, INC.
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 11
Telix Pharmaceuticals Limited (ASX:TLX) completed the acquisition of IsoTherapeutics Group, LLC for $8.1 million. Apr 09
Telix Pharmaceuticals Limited Announces First Patient Dosed in Italian Named Patient ( Early Access) Program for TLX250-CDx Telix's Kidney Cancer Imaging Agent Mar 26
Consensus EPS estimates fall by 19% Mar 14
Price target increased by 7.5% to AU$14.47 Mar 11 Telix Pharmaceuticals Limited (ASX:TLX) signed an agreement to acquire ARTMS, INC. for approximately $84 million. Mar 05
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire IsoTherapeutics Group, LLC for $13.6 million. Feb 27
Full year 2023 earnings released: EPS: AU$0.016 (vs AU$0.34 loss in FY 2022) Feb 23 Telix Pharmaceuticals Limited, Annual General Meeting, May 22, 2024
Co-Founder exercised options to buy AU$1.7m worth of stock. Jan 23
Telix Pharmaceuticals Limited to Report Fiscal Year 2023 Results on Feb 22, 2024 Jan 08
Forecast breakeven date pushed back to 2024 Dec 31
Telix Pharmaceuticals Limited Announces Executive Changes Dec 20
Telix Pharmaceuticals Limited Submits Biologics License Application for TLX250-CDx (Zircaix) for Imaging of Kidney Cancer Dec 19
Telix Pharmaceuticals Limited Announces First Patient Dosed in European Named Patient ( Early Access) Program for TLX250-CDx, Telix's Kidney Cancer Imaging Agent Dec 04
Telix Pharmaceuticals Limited Announces Phase II OPALESCENCE Study of TLX250-CDx in Triple Negative Breast Cancer to be Presented at SABCS Nov 30
Price target increased by 8.0% to AU$13.37 Nov 22
Telix Pharmaceuticals Limited (ASX:TLX) signed a non-binding term sheet to acquire QSAM Biosciences, Inc. (OTCPK:QSAM) for $33.1 million. Nov 15
Telix Pharmaceuticals Limited (ASX:TLX) acquired Lightpoint Surgical Limited from Lightpoint Medical, Ltd AUD 51 million. Nov 02
Telix Pharmaceuticals Limited Announces Positive Preliminary Results from the Phase I ProstACT SELECT Study of Its rADC Therapy Candidate TLX591 Oct 19
Telix Pharmaceuticals Limited Announces First Patients Dosed in Chinese Imaging Studies Oct 18
Telix Pharmaceuticals Limited to Report Q3, 2023 Results on Oct 18, 2023 Oct 11
New minor risk - Shareholder dilution Sep 06
Forecast to breakeven in 2023 Aug 25
First half 2023 earnings released: AU$0.045 loss per share (vs AU$0.23 loss in 1H 2022) Aug 24
Forecast to breakeven in 2023 Aug 24
Forecast breakeven date moved forward to 2023 Aug 23
Telix Pharmaceuticals Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 15
Forecast to breakeven in 2023 Jul 21
Telix Pharmaceuticals Limited to Report Q2, 2023 Results on Jul 19, 2023 Jul 13
Telix Pharmaceuticals Limited to Showcase ZIRCON Phase III Kidney Cancer Imaging Data and Theranostic Pipeline Developments at SNMMI Jun 24
Telix Pharmaceuticals Limited (ASX:TLX) entered into an agreement to acquire Lightpoint Surgical Limited from Lightpoint Medical, Ltd for AUD 51 million. Jun 22
Telix Pharmaceuticals Limited Announces First Patient Dosed in Phase II STARBURST Study of TLX250-CDx Exploring Indication Expansion Jun 19
Price target increased by 7.5% to AU$11.82 Jun 06
Price target increased by 8.8% to AU$10.54 Apr 28
Price target increased by 8.8% to AU$10.54 Apr 19
Insider recently bought AU$343k worth of stock Mar 18
Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind Feb 28
Telix Pharmaceuticals Limited Announces Detailed Positive Results from its Completed Pivotal Phase III ZIRCON Trial Feb 20
Consensus EPS estimates fall by 14%, revenue upgraded Jan 25
Forecast breakeven date pushed back to 2024 Jan 18
Telix Pharmaceuticals Limited to Report Q4, 2022 Results on Jan 18, 2023 Jan 12
Telix Pharmaceuticals Limited Announces ZIRCON Phase III Renal Cancer Study to be Presented at ASCO GU along with Theranostic Pipeline Advances Dec 22
Insider recently bought AU$73k worth of stock Dec 16
Telix Pharmaceuticals Limited Announces Leadership Changes Dec 05
Telix Pharmaceuticals Limited Announces Illuccix Kit for the Preparation of Gallium Ga 68 Gozetotide Injection Nov 23
Telix Pharmaceuticals Limited Announces That First Patient Dosed in Phase II 'IPAX-Linz' Study of TLX101 for Glioblastoma Therapy Nov 22
Non-Executive Director exercised options to buy AU$3.5m worth of stock. Nov 16
Insufficient new directors Nov 16
Telix Pharmaceuticals Limited (ASX:TLX) agreed to acquire Optimal Tracers from Northern California PET Imaging Center. Nov 15
Telix Pharmaceuticals Limited Announces Positive Topline Results from Overseas Phase III Clinical Trial Has Met Clinical Endpoints Nov 11
Non-Executive Director exercised options to buy AU$3.4m worth of stock. Nov 11
Telix Pharmaceuticals Limited Announces Positive Topline Results of ZIRCON Phase III Kidney Cancer Imaging Study Nov 07
Forecast breakeven date moved forward to 2023 Oct 21
Consensus revenue estimates increase by 19% Oct 21
Telix Pharmaceuticals Limited Presents Preliminary Data on TLX250-CDx Indication Expansion at EANM Oct 18 Telix Pharmaceuticals Limited to Report Q3, 2022 Results on Oct 20, 2022 Telix Pharmaceuticals Limited Announces Health Canada Approves Illuccix for Prostate Cancer Imaging Oct 14
Telix Pharmaceuticals Limited Announces First Patient in New Zealand Dosed with Illuccix Sep 30 Rendimenti per gli azionisti TLX AU Biotechs AU Mercato 7D -1.6% 1.9% 0.5% 1Y 144.1% 3.9% 7.4%
Vedi i rendimenti completi degli azionisti
Ritorno vs Industria: TLX ha superato il Australian Biotechs che ha restituito 3.9 % nell'ultimo anno.
Rendimento vs Mercato: TLX ha superato il mercato Australian che ha restituito 7.4 % nell'ultimo anno.
Volatilità dei prezzi Is TLX's price volatile compared to industry and market? TLX volatility TLX Average Weekly Movement 4.2% Biotechs Industry Average Movement 10.0% Market Average Movement 8.0% 10% most volatile stocks in AU Market 16.9% 10% least volatile stocks in AU Market 3.0%
Prezzo delle azioni stabile: TLX non ha avuto una volatilità dei prezzi significativa negli ultimi 3 mesi.
Volatilità nel tempo: La volatilità settimanale ( 4% ) di TLX è rimasta stabile nell'ultimo anno.
Informazioni sull'azienda Fondato I dipendenti AMMINISTRATORE DELEGATO Sito web 2015 423 Chris Behrenbruch telixpharma.com
Telix Pharmaceuticals Limited, una società biofarmaceutica in fase commerciale, si concentra sullo sviluppo e la commercializzazione di radiofarmaci terapeutici e diagnostici per il cancro e le malattie rare in Australia, Belgio, Giappone, Svizzera e Stati Uniti. L'azienda offre Illuccix per il trattamento del cancro alla prostata e TLX66-CDx per il trattamento dell'osteomielite per immagini. I suoi prodotti candidati includono TLX591, un coniugato anticorpo-farmaco per il trattamento del cancro alla prostata; TLX250-CDx per il trattamento e la diagnosi del cancro renale; TLX101-CDx per il cancro al cervello (glioma); TLX66-CDx per il trattamento del condizionamento del midollo osseo; TLX300-CDx per il trattamento e la diagnosi del sarcoma dei tessuti molli; e TLX250 per il trattamento del carcinoma renale a cellule chiare.
Mostra di più Telix Pharmaceuticals Limited Riepilogo dei fondamenti Come si confrontano gli utili e i ricavi di Telix Pharmaceuticals con la sua capitalizzazione di mercato? TLX statistiche fondamentali Capitalizzazione di mercato AU$8.24b Guadagni(TTM ) AU$49.19m Ricavi(TTM ) AU$645.68m
Guadagni e ricavi Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM) TLX Conto economico (TTM ) Ricavi AU$645.68m Costo del fatturato AU$240.33m Profitto lordo AU$405.35m Altre spese AU$356.16m Guadagni AU$49.19m
Ultimi guadagni dichiarati
Jun 30, 2024
Prossima data di guadagno
n/a
Utile per azione (EPS) 0.15 Margine lordo 62.78% Margine di profitto netto 7.62% Rapporto debito/patrimonio netto 2.9%
Come si è comportato TLX nel lungo periodo?
Vedi performance storica e confronto
Analisi aziendale e situazione dei dati finanziari Dati Ultimo aggiornamento (ora UTC) Analisi dell'azienda 2024/12/31 07:50 Prezzo dell'azione a fine giornata 2024/12/31 00:00 Guadagni 2024/06/30 Guadagni annuali 2023/12/31
Fonti dei dati I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC . I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.
Pacchetto Dati Tempistica Esempio Fonte USA * Dati finanziari della società 10 anni Conto economico Rendiconto finanziario Bilancio Stime di consenso degli analisti +3 anni Previsioni finanziarie Obiettivi di prezzo degli analisti Prezzi di mercato 30 anni Prezzi delle azioni Dividendi, scissioni e azioni Proprietà 10 anni Top azionisti Insider trading Gestione 10 anni Team di leadership Consiglio di amministrazione Sviluppi principali 10 anni
* esempio per i titoli statunitensi, per quelli non statunitensi si utilizzano forme e fonti normative equivalenti.
Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più , cliccate qui .
Modello di analisi e Snowflake I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github ; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube .
Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.
Metriche di settore e industriali Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su .
Fonti analitiche Telix Pharmaceuticals Limited è coperta da 14 analisti. 9 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.
Analista Istituzione Russell Wright Barclay Pearce Capital Pty Limited John Hester Bell Potter Andrew Paine CLSA
Mostra 11 altri analisti 
